Ubs Group Ag Inozyme Pharma, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 25,764 shares of INZY stock, worth $77,034. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,764

Previous 15,773 63.34%

Holding current value

$77,034

Previous $70,000 91.43%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$4.31 - $6.0 $43,061 - $59,946	9,991 Added 63.34%	25,764 $134,000
Q2 2024 Aug 13, 2024	SELL	$4.33 - $7.31 $139,369 - $235,286	-32,187 Reduced 67.11%	15,773 $70,000
Q1 2024 May 13, 2024	BUY	$4.14 - $7.66 $7,257 - $13,427	1,753 Added 3.79%	47,960 $367,000
Q4 2023 Feb 09, 2024	BUY	$2.71 - $4.5 $73,955 - $122,805	27,290 Added 144.26%	46,207 $196,000
Q3 2023 Nov 09, 2023	SELL	$4.09 - $7.0 $10,879 - $18,620	-2,660 Reduced 12.33%	18,917 $79,000
Q2 2023 Aug 11, 2023	BUY	$4.93 - $6.74 $106,374 - $145,428	21,577 New	21,577 $120,000
Q4 2022 Feb 08, 2023	BUY	$1.05 - $2.82 $2,975 - $7,991	2,834 New	2,834 $2,000
Q2 2022 Aug 10, 2022	SELL	$3.2 - $5.96 $19,833 - $36,940	-6,198 Reduced 98.18%	115 $1,000
Q1 2022 May 16, 2022	SELL	$3.87 - $7.55 $3,541 - $6,908	-915 Reduced 12.66%	6,313 $26,000
Q4 2021 Feb 14, 2022	BUY	$5.58 - $11.5 $40,332 - $83,122	7,228 New	7,228 $49,000
Q3 2021 Nov 15, 2021	SELL	$11.12 - $19.4 $533 - $931	-48 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$15.19 - $21.2 $14,491 - $20,224	-954 Reduced 95.21%	48 $1,000
Q1 2021 May 12, 2021	BUY	$17.77 - $27.9 $17,805 - $27,955	1,002 New	1,002 $20,000
Q4 2020 Feb 11, 2021	SELL	$19.95 - $27.55 $10,693 - $14,766	-536 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$17.54 - $30.2 $9,401 - $16,187	536 New	536 $14,000

Others Institutions Holding INZY

# of Institutions

Shares Held

53M

Call Options Held

3.7K

Put Options Held

5.8K

View Full List

About Inozyme Pharma, Inc.

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $120M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

More about INZY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account